Stopping a GLP-1: what the evidence says about weight regain

The BMJ study (DOI: 10.1136/bmj-2025-085304), published in 2026, conducted a systematic review and meta-analysis of weight regain after stopping weight-management medications in adults with overweight or obesity. The analysis included data on GLP-1 medications including semaglutide and tirzepatide.

The headline finding: after stopping, patients regain weight at an average rate of approximately 0.4 kilograms per month. At that pace, full prior weight loss is projected to be regained in roughly 1.7 years from the stop date, based on TCTMD's reporting of the study's projections.

The BMJ also found that approximately 50% of people with obesity discontinue GLP-1 receptor agonists within 12 months of starting — suggesting the stopping question is not hypothetical for a large proportion of patients who begin these medications.

A companion analysis published in Lancet eClinicalMedicine in 2026 noted that prescribing guidelines are largely inadequate for addressing the weight regain risk that follows discontinuation. In other words, the clinical field has better evidence for starting GLP-1 therapy than for planning what happens after it ends.

The average trajectory from the BMJ meta-analysis is not the only data point. A Cleveland Clinic analysis of nearly 8,000 patients who stopped semaglutide or tirzepatide found a more heterogeneous picture: 45% of patients maintained their weight or continued losing weight in the year after stopping. Twenty-seven percent switched to a different weight-management medication, and 20% restarted their original GLP-1 drug.

This Cleveland Clinic study, led by Dr. Hamlet Gasoyan and published in Diabetes, Obesity and Metabolism, suggests that patient outcomes after stopping GLP-1s depend substantially on what happens next — including whether patients have clinical support, switching options, or restart pathways. The average meta-analysis figure does not capture this variation.

A separate study from Washington University School of Medicine (BMJ Medicine, March 2026), analyzing data from over 333,000 veterans, added a cardiovascular dimension: stopping GLP-1 therapy for as little as six months was associated with up to 22% increased risk of major cardiovascular events compared to continued use. Cardiovascular benefit appears to accumulate over years but erode quickly after stopping.

GLP-1 receptor agonists work by suppressing appetite signals, slowing gastric emptying, and modulating the brain's reward and energy-balance pathways. When the medication stops, those effects stop. The physiological drive toward higher body weight — which includes complex hormonal and neurological systems — reasserts. For most people, this means weight comes back.

This is a pharmacological outcome, not a measure of willpower or discipline. Understanding this matters because it changes what questions are worth asking: not "why did I regain weight?" but "what maintenance plan was in place, and what are my options now?"

Several 2026 trials address the question of what to do instead of simply stopping:

SURMOUNT-MAINTAIN (Lancet, 2026, 112-week data): participants who reduced tirzepatide from their maximum tolerated dose to 5 mg maintained 77.5% of their prior weight loss, versus 10.4% on placebo. Continuing at the original dose maintained the full prior weight loss.

ATTAIN-MAINTAIN (Nature Medicine, 2026): participants who switched from injectable semaglutide or tirzepatide to oral orforglipron (Foundayo) preserved 74.7–79.3% of prior weight loss at 52 weeks, versus 38–49% on placebo.

Neither of these trials is a treatment protocol — they are evidence that tapering or stepping down is not equivalent to stopping, and that alternatives to abrupt discontinuation may significantly change the weight trajectory. Whether either approach is right for you is a clinical conversation.

The BMJ meta-analysis reports averages — it does not predict any individual patient's experience. Factors including baseline metabolic profile, dietary habits, physical activity, and clinical follow-up all influence what happens after stopping.

The best strategies for minimizing regain are still being developed. The new maintenance trial data offer options but are not yet embedded in clinical guidelines. Many prescribers may not yet be aware of SURMOUNT-MAINTAIN or ATTAIN-MAINTAIN findings.

• What is the plan for managing weight if I stop or reduce this medication?
• Is a dose reduction or step-down strategy an option for me, rather than stopping entirely?
• How will we track my weight trajectory after any change, and when would we consider restarting?
• Does my cardiovascular risk profile change the calculus on stopping?
• What role does continued exercise and protein intake play in reducing regain after stopping?

---

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• BMJ 2026: Weight regain after cessation of medication for weight management. DOI: 10.1136/bmj-2025-085304. bmj.com
• TCTMD: Weight Regained Within 18 Months of Stopping GLP-1 Drugs. tctmd.com
• BMJ Group press release: Stopping weight loss drugs linked to weight regain and reversal of heart health markers. bmjgroup.com
• Lancet eClinicalMedicine 2026 companion analysis (PIIS2589-5370(26)00043-X). thelancet.com
• Cleveland Clinic / Gasoyan et al. — real-world study, Diabetes Obesity and Metabolism. newsroom.clevelandclinic.org
• WashU / Al-Aly, BMJ Medicine, March 2026. medicine.washu.edu